Skip to content

Ego dissolution: all studies

Page 36 of 57: studies 351 to 360 of 562, newest first. Back to the ego dissolution overview

Research

Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer's Disease and Related Dementias.

AJOB Neuroscience 2023 Andrew Peterson, Emily A Largent, Holly Fernandez Lynch et al. 42 citations

In this paper, we examine the case of psychedelic medicine for Alzheimer's disease and related dementias (AD/ADRD). These "mind-altering" drugs are not currently offered as treatments to persons with AD/ADRD, though there is growing interest in their use to treat underlying causes and associated psychiatric symptoms. We present a research agenda for examining the ethics of psychedelic medicine...

DOI: 10.1080/21507740.2022.2148771 (opens in new tab) Full text (opens in new tab) Alzheimer’s disease Dementia Drug use Psychoactive drugs

Touching and being touched: where knowing and feeling meet.

Frontiers in Psychology 2023 Lawrence Fischman 2 citations

Philosophers maintain that touch confers a sense of reality or grounding to perceptual experience. In touching oneself, one is simultaneously both subject and object of touch, a template for experiencing oneself as subject and object of intentions, feelings, and motivations, or intersubjectivity. Here, I explore a form of self-touch carefully documented by Winnicott in observing how the infant...

DOI: 10.3389/fpsyg.2023.1097402 (opens in new tab) Full text (opens in new tab) Absorption Depersonalization Empathy Mind-wandering +3

Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users

Journal of Cognitive Neuroscience 2023 Johannes G. Ramaekers, Pablo Mallaroni, Lilian Kloft et al. 15 citations

Abstract Consumption of the psychedelic brew ayahuasca is a central ritualistic aspect of the Santo Daime religion. The current observational, baseline controlled study was designed to assess whether members (n = 24) of the Santo Daime church would show enhanced capacity for mental imagery during an ayahuasca experience. In addition, this study assessed whether the effects of ayahuasca on...

DOI: 10.1162/jocn_a_02003 (opens in new tab) Ayahuasca DMT Psychedelics Consciousness research +1

This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience.

Frontiers in Psychology 2023 Pascal Michael, David Luke, Oliver Robinson 19 citations

Much research has focused on the modeling of the near-death experience (NDE) by classical and atypical psychedelics; however, to date, no study has reported on the relationship between the NDE and the experience induced by the highly potent, endogenous psychedelic drug 5-Methoxy-DMT (5MeO-DMT). This article presents a case study of an individual who is popularly documented to have had a...

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.

Frontiers in Psychiatry 2023 Ellen James, David Erritzøe, Tiffanie Benway et al. 16 citations

Due to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) in the treatment of major depressive disorder (MDD). The aim of Part A of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) profile of escalating doses of SPL026 (DMT fumarate)...

A unified model of ketamine's dissociative and psychedelic properties.

Journal of Psychopharmacology December 17, 2022 Miriam Marguilho, Inês Figueiredo, Pedro Castro-Rodrigues 57 citations

Ketamine is an N-methyl-d-aspartate antagonist which is increasingly being researched and used as a treatment for depression. In low doses, it can cause a transitory modification in consciousness which was classically labelled as ‘dissociation’. However, ketamine is also commonly classified as an atypical psychedelic and it has been recently reported that ego dissolution experiences during...

DOI: 10.1177/02698811221140011 (opens in new tab) Full text (opens in new tab) Psychopharmacology Mental health Consciousness research Ketamine therapy

Altered States of Consciousness During Ceremonial San Pedro Use

International Journal for the Psychology of Religion December 5, 2022 Arne Bohn, Michiel H. H. Kiggen, Malin V. Uthaug et al. 10 citations

San Pedro, a mescaline containing cactus, has been used for thousands of years and is currently popular as a psychedelic substance in ceremonial retreats in Europe. The current research investigates the consciousness altering effects of San Pedro. Forty-two participants who joined ceremonial psychedelic retreats in the Netherlands were investigated with questionnaires probing 11 dimensions of...

Ayahuasca Self Consciousness and Mysticism

November 24, 2022 Robson Savoldi, Antônio Roazzi preprint

Recent studies have assessed that the mystical alterations in sense of self are the best candidates for improvements in self-consciousness and the therapeutic potentials of ayahuasca’s rituals. Here, we examine the predictive relations of self-consciousness by mysticism and ego-dissolution self-reports. A cross-sectional study was drawn to investigate which self-consciousness traits – private...

An Experimental Study of Subliminal Self-Face Processing in Depersonalization-Derealization Disorder.

Brain Sciences November 22, 2022 Shanshan Liu, Yuan Jia, Sisi Zheng et al.

The self-perception or self-experience of patients with depersonalization/derealization disorder (DPD) is altered, leading to a profound disruption in self-awareness. The main aim of the study is to explore the characteristics of subliminal self-face processing in DPD patients. To our knowledge, this is the first experimental study that has measured and evaluated subliminal self-processing in...

DOI: 10.3390/brainsci12121598 (opens in new tab) Full text (opens in new tab) Subliminal Continuous flash suppression Depersonalization/derealization disorder Self-face advantage +1

Body mass index (BMI) does not predict responses to psilocybin

Journal of Psychopharmacology November 14, 2022 Meg J. Spriggs, Bruna Giribaldi, Taylor Lyons et al. 15 citations

Background: Psilocybin is a serotonin type 2A (5-HT 2A ) receptor agonist and naturally occurring psychedelic. 5-HT 2A receptor density is known to be associated with body mass index (BMI), however, the impact of this on psilocybin therapy has not been explored. While body weight-adjusted dosing is widely used, this imposes a practical and financial strain on the scalability of psychedelic...